Medequip and Neolight Bring ROP Screening Innovation to KwaZulu-Natal

Last week, Medequip proudly joined forces with our trusted supplier Neolight for a KZN Roadshow, where we showcased the groundbreaking Neolight ROP Screening Device to healthcare professionals across the province.

Why ROP Screening Matters

Retinopathy of Prematurity (ROP) is a potentially blinding eye disorder that affects premature infants, caused by abnormal blood vessel development in the retina. Early detection through ROP screening is critical — with timely diagnosis and treatment, permanent vision loss can often be prevented.

The Neolight ROP Screening Device represents a significant advancement in neonatal care. It offers a safer, faster, and more accessible way for clinicians to identify early signs of ROP, supporting better patient outcomes and more confident clinical decision-making.

A Shared Commitment to Better Care

Through this collaboration, Medequip and Neolight are reaffirming their shared commitment to improving neonatal health and expanding access to innovative medical technology across South Africa.

“Our goal is to ensure that healthcare professionals have the tools they need to protect every baby’s sight,” says the Medequip team. “We’re proud to work alongside Neolight to make that vision a reality.”

Together, we continue to champion innovation, collaboration, and compassionate care — because every baby deserves the best start in sight. 👁️💙